In January, Jeff La Marca got a prescription for the popular weight loss drug Zepbound. But he couldn't afford the $750 monthly price tag. This story was produced in partnership with KFF Health News.
Then Medicare launched an 18-month pilot program that offers GLP-1 medications to some enrollees for only $50 a month. La Marca thought he might finally be able to afford the drug. "I thought, 'Thank God, there's a path,'" said La Marca, who lives in Basking Ridge, N.J., and has tried numerous diets and exercise regimes.
But the 68-year-old's celebration was short-lived. His application to the pilot program was denied. La Marca has severe obstructive sleep apnea, one of several diagnoses that exclude patients from the Medicare GLP-1 Bridge program's $50 monthly price.
The notification didn't say why he was rejected. He thinks that if he didn't have that diagnosis, he would qualify due to his weight. "I'm obese, morbidly obese, BMI 42.
I had quadruple heart bypass surgery. About 1 in 5 American adults has taken a GLP-1 medication, and most of them, including those with health insurance, say the drugs are difficult to afford. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, which is why the Medicare GLP-1 Bridge program made a big splash when it launched in July.
It's a short-term pilot program in which Medicare is offering coverage of three GLP-1s for weight loss and management, to see whether that would save Medicare money later. Eligible patients must be enrolled in Medicare Part D, a prescription drug coverage add-on to Medicare. Even though people must have Part D insurance to qualify, the preauthorization request doesn't go through the insurer; it's instead submitted to a separate system run by a contractor for the Centers for Medicare & Medicaid Services.
Extract — continue reading at the source.
